CJC-1295/Ipamorelin improves insulin sensitivity and glucose disposal through growth hormone's metabolic effects. Adding AOD-9604 (a lipolytic fragment) enhances fat oxidation without affecting blood sugar. Tesamorelin has also shown improvements in insulin sensitivity. Studies in
Diabetes Care demonstrate GH optimization improves metabolic parameters, though monitoring glucose is advisable during initial weeks of therapy.